Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 10/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | CPS1 | P31327 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4636549 | 0.85 | CPS1 (0.53) | CPS1 | |
| SCHEMBL4898713 | 0.81 | HCRTR1 (0.57) | HCRTR1HCRTR2CPS1P2RX7 | |
| SCHEMBL4635067 | 0.79 | HSD11B1 (0.51) | HSD11B1 | |
| SCHEMBL4635777 | 0.77 | KMT2A (0.44) | PDE2AHSD11B1 | |
| SCHEMBL4635120 | 0.76 | PAX8 (0.42) | HCRTR1HCRTR2HSD11B1 | |
| SCHEMBL4636613 | 0.75 | CES2 (0.46) | HCRTR1HCRTR2CPS1 | |
| SCHEMBL4636539 | 0.74 | TSHR (0.46) | HCRTR1HCRTR2CPS1 | |
| SCHEMBL3390817 | 0.74 | PDE2A (0.56) | PDE2AHSD11B1 | |
| SCHEMBL3390823 | 0.74 | PDE2A (0.56) | PDE2AHSD11B1 | |
| SCHEMBL4635404 | 0.74 | PLA2G7 (0.60) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
| EP-1931633-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007029086-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP8 | HCRTR1 1802/4885HCRTR2 1658/4885PDE2A 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.